Journal for ImmunoTherapy of Cancer: 9 (2)

Editorial

Real-world insights on preferred treatments for steroid-refractory immune checkpoint inhibitor-induced pneumonitis (18 February, 2021)
Margaret Gatti-Mays, James L Gulley

Basic tumor immunology

Original research: TGFβ1 neutralization displays therapeutic efficacy through both an immunomodulatory and a non-immune tumor-intrinsic mechanism (26 February, 2021)
Stefania Canè, Jacques Van Snick, Catherine Uyttenhove, Luc Pilotte, Benoit J Van den Eynde
Original research: Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia (17 February, 2021)
Daniele Caracciolo, Caterina Riillo, Andrea Ballerini, Giuseppe Gaipa, Ludovic Lhermitte, Marco Rossi, Cirino Botta, Eugénie Duroyon, Katia Grillone, Maria Eugenia Gallo Cantafio, Chiara Buracchi, Greta Alampi, Alessandro Gulino, Beatrice Belmonte, Francesco Conforti, Gaetanina Golino, Giada Juli, Emanuela Altomare, Nicoletta Polerà, Francesca Scionti, Mariamena Arbitrio, Michelangelo Iannone, Massimo Martino, Pierpaolo Correale, Gabriella Talarico, Andrea Ghelli Luserna di Rorà, Anna Ferrari, Daniela Concolino, Simona Sestito, Licia Pensabene, Antonio Giordano, Markus Hildinger, Maria Teresa Di Martino, Giovanni Martinelli, Claudio Tripodo, Vahid Asnafi, Andrea Biondi, Pierosandro Tagliaferri, Pierfrancesco Tassone
Original research: Nanoencapsulated rituximab mediates superior cellular immunity against metastatic B-cell lymphoma in a complement competent humanized mouse model (16 February, 2021)
Jing Wen, Lan Wang, Jie Ren, Emiko Kranz, Shilin Chen, Di Wu, Toshio Kanazawa, Irvin Chen, Yunfeng Lu, Masakazu Kamata
Original research: Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators (15 February, 2021)
Jiakai Hou, Yunfei Wang, Leilei Shi, Yuan Chen, Chunyu Xu, Arash Saeedi, Ke Pan, Ritu Bohat, Nicholas A. Egan, Jodi A. McKenzie, Rina M. Mbofung, Leila J. Williams, Zhenhuang Yang, Ming Sun, Xiaofang Liang, Jordi Rodon Ahnert, Navin Varadarajan, Cassian Yee, Yiwen Chen, Patrick Hwu, Weiyi Peng
Original research: Phosphorylation of SMAD3 in immune cells predicts survival of patients with early stage non-small cell lung cancer (15 February, 2021)
Sebastian Marwitz, Carmen Ballesteros-Merino, Shawn M Jensen, Martin Reck, Christian Kugler, Sven Perner, Daniel Drömann, Torsten Goldmann, Bernard A Fox
Original research: Quantitative systems pharmacology model predictions for efficacy of atezolizumab and nab-paclitaxel in triple-negative breast cancer (12 February, 2021)
Hanwen Wang, Huilin Ma, Richard J Sové, Leisha A Emens, Aleksander S Popel
Original research: STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment (1 February, 2021)
Manoj Chelvanambi, Ronald J Fecek, Jennifer L Taylor, Walter J Storkus

Case report

αPD-1-mesoCAR-T cells partially inhibit the growth of advanced/refractory ovarian cancer in a patient along with daily apatinib (15 February, 2021)
Juemin Fang, Na Ding, Xianling Guo, Yan Sun, Zhiwei Zhang, Bailu Xie, Zhong Li, Hui Wang, Wei Mao, Zhicai Lin, Fei Qin, Min Yuan, Wenqi Chu, Huanlong Qin, Qijun Qian, Qing Xu
Adrenal gland as a sanctuary site for immunotherapy in patients with microsatellite instability-high metastatic colorectal cancer (12 February, 2021)
Romain Cohen, Vincent Jonchère, Christelle De La Fouchardière, Toky Ratovomanana, Quentin Letourneur, Mira Ayadi, Lucile Armenoult, Adrien Buisson, Matthieu Sarabi, Anna Pellat, Raphael Colle, Francois Paye, Pierre Meeus, Magali Svrcek, Alex Duval, Thierry Andre
COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report (11 February, 2021)
Angelo Dipasquale, Pasquale Persico, Elena Lorenzi, Daoud Rahal, Armando Santoro, Matteo Simonelli
Short-term response to immune-chemotherapy and immune features of a ceritinib-resistant patient with ROS1-rearranged lung adenocarcinoma
(8 February, 2021)
Dongsheng Yue, Juanjuan Qian, Zhipeng Chen, Bin Zhang, Peng Chen, Lei Zhang, Jingjing Li, Henghui Zhang, Changli Wang

Clinical/translational cancer immunotherapy

Original research: Frequent amplification of HDAC genes and efficacy of HDAC inhibitor chidamide and PD-1 blockade combination in soft tissue sarcoma (26 February, 2021)
Yi Que, Xiao-Long Zhang, Ze-Xian Liu, Jing-Jing Zhao, Qiu-Zhong Pan, Xi-Zhi Wen, Wei Xiao, Bu-Shu Xu, Dong-Chun Hong, Tian-Hui Guo, Lu-Jun Shen, Wei-Jun Fan, Huo-Ying Chen, De-Sheng Weng, Hai-Rong Xu, Peng-Hui Zhou, Yi-Zhuo Zhang, Xiao-Hui Niu, Xing Zhang
Original research: Post-transplantation cyclophosphamide reduces the incidence of acute graft-versus-host disease in patients with acute myeloid leukemia/myelodysplastic syndromes who receive immune checkpoint inhibitors after allogeneic hematopoietic stem cell transplantation (26 February, 2021)
Chantal Saberian, Noha Abdel-Wahab, Ala Abudayyeh, Hind Rafei, Jacinth Joseph, Gabriela Rondon, Laura Whited, Stephen Gruschkus, Faisal Fa'ak, May Daher, Cristina Knape, Houssein Safa, Mahran Shoukier, Maria E Suarez-Almazor, Megan Marcotulli, Kaysia Ludford, Alison M Gulbis, Marina Konopleva, Maro Ohanian, Farhad Ravandi, Guillermo Garcia-Manero, Betul Oran, Uday R Popat, Rotesh Mehta, Amin M Alousi, Naval Daver, Richard Champlin, Adi Diab, Gheath Al-Atrash
Original research: Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort (25 February, 2021)
Xue Bai, Michelle Kim, Gyulnara Kasumova, Lu Si, Bixia Tang, Chuanliang Cui, Xiaoling Yang, Xiaoting Wei, Justine Cohen, Donald Lawrence, Christine Freedman, Riley Fadden, Krista Rubin, Tatyana Sharova, Dennie Frederick, Keith Flaherty, Ryan Sullivan, Jun Guo, Genevieve Boland
Original research: Integrative transcriptome analysis of malignant pleural mesothelioma reveals a clinically relevant immune-based classification (25 February, 2021)
Ania Alay, David Cordero, Sara Hijazo-Pechero, Elisabet Aliagas, Adriana Lopez-Doriga, Raúl Marín, Ramón Palmero, Roger Llatjós, Ignacio Escobar, Ricard Ramos, Susana Padrones, Víctor Moreno, Ernest Nadal, Xavier Solé
Original research: Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin’s lymphoma (19 February, 2021)
Kathryn Lurain, Ramya Ramaswami, Ralph Mangusan, Anaida Widell, Irene Ekwede, Jomy George, Richard Ambinder, Martin Cheever, James L Gulley, Priscila H Goncalves, Hao-Wei Wang, Thomas S Uldrick, Robert Yarchoan
Original research: Phase I study of ABBV-428, a mesothelin-CD40 bispecific, in patients with advanced solid tumors (19 February, 2021)
Jason J Luke, Fabrice Barlesi, Ki Chung, Anthony W Tolcher, Karen Kelly, Antoine Hollebecque, Christophe Le Tourneau, Vivek Subbiah, Frank Tsai, Steven Kao, Philippe A Cassier, Mustafa Khasraw, Hedy L Kindler, Hua Fang, Frances Fan, Kathryn Allaire, Maulik Patel, Shiming Ye, Debra T Chao, William R Henner, Joel S Hayflick, Michael A McDevitt, Lawrence Fong
Original research: In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity (19 February, 2021)
Adrianne L Jenner, Tyler Cassidy, Katia Belaid, Marie-Claude Bourgeois-Daigneault, Morgan Craig
Original research: Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve (18 February, 2021)
Kellsye P Fabian, Michelle R Padget, Rika Fujii, Jeffrey Schlom, James W Hodge
Original research: Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung (17 February, 2021)
Elizabeth Dudnik, Samuel Kareff, Mor Moskovitz, Chul Kim, Stephen V Liu, Anastasiya Lobachov, Teodor Gottfried, Damien Urban, Alona Zer, Ofer Rotem, Amir Onn, Mira Wollner, Jair Bar
Original research: SARS-CoV-2 infection and adverse events in patients with cancer receiving immune checkpoint inhibitors: an observational prospective study (16 February, 2021)
Mario Mandala, Paul Lorigan, Matilde De Luca, Andrea Bianchetti, Barbara Merelli, Anna Cecilia Bettini, Lucia Bonomi, Sharon Nahm, Maria Grazia Vitale, Giorgia Negrini, Andrea Di Croce, Paolo Antonio Ascierto, Eliana Rulli, Carlo Alberto Tondini
Original research: Activation of MAT2A-RIP1 signaling axis reprograms monocytes in gastric cancer (16 February, 2021)
Yan Zhang, Hui Yang, Jun Zhao, Ping Wan, Ye Hu, Kun Lv, YiRen Hu, Xi Yang, Mingzhe Ma
Original research: WHSC1/NSD2 regulates immune infiltration in prostate cancer (15 February, 2021)
Muzamil Y Want, Takemasa Tsuji, Prashant K Singh, James L Thorne, Junko Matsuzaki, Ellen Karasik, Bryan Gillard, Eduardo Cortes Gomez, Richard C. Koya, Amit Lugade, Kunle Odunsi, Sebastiano Battaglia
Original research: TGFβ drives NK cell metabolic dysfunction in human metastatic breast cancer (10 February, 2021)
Karen Slattery, Elena Woods, Vanessa Zaiatz-Bittencourt, Sam Marks, Sonya Chew, Michael Conroy, Caitriona Goggin, Colm MacEochagain, John Kennedy, Sophie Lucas, David K Finlay, Clair M Gardiner
Original research: Success and failure of additional immune modulators in steroid-refractory/resistant pneumonitis related to immune checkpoint blockade (10 February, 2021)
Jason Beattie, Hira Rizvi, Paige Fuentes, Jia Luo, Adam Schoenfeld, I-Hsin Lin, Michael Postow, Margaret Callahan, Martin H Voss, Neil J Shah, Allison Betof Warner, Mohit Chawla, Matthew D Hellmann
Original research: Ipilimumab and nivolumab/pembrolizumab in advanced hepatocellular carcinoma refractory to prior immune checkpoint inhibitors (9 February, 2021)
Jeffrey Sum Lung Wong, Gerry Gin Wai Kwok, Vikki Tang, Bryan Cho Wing Li, Roland Leung, Joanne Chiu, Ka Wing Ma, Wong Hoi She, Josephine Tsang, Chung Mau Lo, Tan To Cheung, Thomas Yau
Original research: Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression (9 February, 2021)
Stefano Pierini, Abhishek Mishra, Renzo Perales-Linares, Mireia Uribe-Herranz, Silvia Beghi, Andrea Giglio, Sergei Pustylnikov, Francesca Costabile, Stavros Rafail, Augusto Amici, John G Facciponte, Costantinos Koumenis, Andrea Facciabene
Original research: Characterizing tumor shrinkage as a measure of clinical benefit for immune checkpoint inhibitors (8 February, 2021)
Thomas Kelleher, Junliang Cai, Nicholas AJ Botwood, Dominic F Labriola

Commentary

Immune checkpoint inhibitor-related hypogonadism and infertility: a neglected issue in immuno-oncology (15 February, 2021)
Berna C Özdemir

Immunotherapy biomarkers

Original research: Impact of C-reactive protein flare-response on oncological outcomes in patients with metastatic renal cell carcinoma treated with nivolumab (18 February, 2021)
Shohei Fukuda, Kazutaka Saito, Yosuke Yasuda, Toshiki Kijima, Soichiro Yoshida, Minato Yokoyama, Junichiro Ishioka, Yoh Matsuoka, Yukio Kageyama, Yasuhisa Fujii
Original research: Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of patients with recurrent/metastatic cancer to immune checkpoint inhibitors (16 February, 2021)
Jian-Guo Zhou, Anna-Jasmina Donaubauer, Benjamin Frey, Ina Becker, Sandra Rutzner, Markus Eckstein, Roger Sun, Hu Ma, Philipp Schubert, Claudia Schweizer, Rainer Fietkau, Eric Deutsch, Udo Gaipl, Markus Hecht
Original research:
Intratumoral CXCL13⁺CD8⁺T cell infiltration determines poor clinical outcomes and immunoevasive contexture in patients with clear cell renal cell carcinoma
(15 February, 2021)
Siyuan Dai, Han Zeng, Zhaopei Liu, Kaifeng Jin, Wenbin Jiang, Zewei Wang, Zhiyuan Lin, Ying Xiong, Jiajun Wang, Yuan Chang, Qi Bai, Yu Xia, Li Liu, Yu Zhu, Le Xu, Yang Qu, Jianming Guo, Jiejie Xu
Original research:
Therapeutic depletion of CCR8⁺ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti-PD-1 therapy
(15 February, 2021)
Helena Van Damme, Bruno Dombrecht, Máté Kiss, Heleen Roose, Elizabeth Allen, Eva Van Overmeire, Daliya Kancheva, Liesbet Martens, Aleksandar Murgaski, Pauline Madeleine Rachel Bardet, Gillian Blancke, Maude Jans, Evangelia Bolli, Maria Solange Martins, Yvon Elkrim, James Dooley, Louis Boon, Julia Katharina Schwarze, Frank Tacke, Kiavash Movahedi, Niels Vandamme, Bart Neyns, Sebahat Ocak, Isabelle Scheyltjens, Lars Vereecke, Frank Aboubakar Nana, Pascal Merchiers, Damya Laoui, Jo Agnes Van Ginderachter
Original research: Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients (15 February, 2021)
Veronica Huber, Lorenza Di Guardo, Luca Lalli, Daniele Giardiello, Agata Cova, Paola Squarcina, Paola Frati, Anna Maria Di Giacomo, Lorenzo Pilla, Marcella Tazzari, Chiara Camisaschi, Flavio Arienti, Chiara Castelli, Monica Rodolfo, Valeria Beretta, Massimo Di Nicola, Michele Maio, Michele Del Vecchio, Filippo de Braud, Luigi Mariani, Licia Rivoltini
Original research: CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer (12 February, 2021)
Qi-Hua Peng, Chun-Hua Wang, Hong-Min Chen, Rong-Xin Zhang, Zhi-Zhong Pan, Zhen-Hai Lu, Gao-Yuan Wang, Xin Yue, Wenlin Huang, Ran-Yi Liu
Original research:
m⁶A modification patterns and tumor immune landscape in clear cell renal carcinoma
(11 February, 2021)
Jiehui Zhong, Zezhen Liu, Chao Cai, Xiaolu Duan, Tuo Deng, Guohua Zeng

Immune cell therapies and immune cell engineering

Original research: 'Off-the-shelf’ allogeneic antigen-specific adoptive T-cell therapy for the treatment of multiple EBV-associated malignancies (15 February, 2021)
Debottam Sinha, Sriganesh Srihari, Kirrliee Beckett, Laetitia Le Texier, Matthew Solomon, Archana Panikkar, George R Ambalathingal, Lea Lekieffre, Pauline Crooks, Sweera Rehan, Michelle A. Neller, Corey Smith, Rajiv Khanna

Oncolytic and local immunotherapy

Original research: Real-life use of talimogene laherparepvec (T-VEC) in melanoma patients in centers in Austria, Switzerland and Germany (19 February, 2021)
Julia Maria Ressler, Matthias Karasek, Lukas Koch, Rita Silmbrod, Joanna Mangana, Sofiya Latifyan, Veronica Aedo-Lopez, Helmut Kehrer, Felix Weihsengruber, Peter Koelblinger, Christian Posch, Julian Kofler, Olivier Michielin, Erika Richtig, Christine Hafner, Christoph Hoeller
Original research: Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy (15 February, 2021)
Nina M. Muñoz, Malea Williams, Katherine Dixon, Crystal Dupuis, Amanda McWatters, Rony Avritscher, Soraya Zorro Manrique, Kevin McHugh, Ravi Murthy, Alda Tam, Aung Naing, Sapna P. Patel, David Leach, Jeffrey D. Hartgerink, Simon Young, Punit Prakash, Patrick Hwu, Rahul A. Sheth
Original research: Intratumoral virotherapy with 4-1BBL armed modified vaccinia Ankara eradicates solid tumors and promotes protective immune memory (12 February, 2021)
Maria Hinterberger, Raphael Giessel, Giovanna Fiore, Fabienne Graebnitz, Barbara Bathke, Sonia Wennier, Paul Chaplin, Ignacio Melero, Mark Suter, Henning Lauterbach, Pedro Berraondo, Hubertus Hochrein, José Medina-Echeverz

Review

CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer (26 February, 2021)
Paola Marie Marcovecchio, Graham Thomas, Shahram Salek-Ardakani
Non-canonical PD-1 signaling in cancer and its potential implications in clinic (16 February, 2021)
Haoran Zha, Ying Jiang, Xi Wang, Jin Shang, Ning Wang, Lei Yu, Wei Zhao, Zhihua Li, Juan An, Xiaochun Zhang, Huoming Chen, Bo Zhu, Zhaoxia Li
Mesenchymal stem cells and oncolytic viruses: joining forces against cancer (8 February, 2021)
Rafael Moreno
Immunotherapy for sarcomas: new frontiers and unveiled opportunities (1 February, 2021)
Harsimrat Kaur Birdi, Anna Jirovec, Serena Cortés-Kaplan, Joel Werier, Carolyn Nessim, Jean-Simon Diallo, Michele Ardolino

Main menu

Table of contents

February 2021 - Volume 9 - 2

Editorial

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Commentary

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Review

Correction

Log in using your username and password

Main menu

Log in using your username and password

You are here

Table of contents

February 2021 - Volume 9 - 2

Editorial

Basic tumor immunology

Case report

Clinical/translational cancer immunotherapy

Commentary

Immunotherapy biomarkers

Immune cell therapies and immune cell engineering

Oncolytic and local immunotherapy

Review

Correction